[Featured Stock] Cellid Rises for Second Day on US-Russia Patents for COVID-19 Vaccine Technology

Cellid has been on the rise for the second consecutive day.

As of 9:45 AM on the 24th, Cellid is trading on the KOSDAQ market at 2,750 KRW, up 465 KRW (20.35%) from the previous trading day.

The day before, Cellid announced that the registration of patents in the United States and Russia for its proprietary adenovirus vector platform technology applied to the COVID-19 vaccine ‘AdCLD-CoV19-1 OMI’ had been approved.

Cellid is a bio-venture company developing cell-based immunotherapeutic vaccines and infectious disease preventive vaccines, established in a laboratory within the College of Pharmacy at Seoul National University.

It specializes in the development of anticancer immunotherapeutic vaccines and COVID-19 preventive vaccines. Its current pipeline includes CeliVax, an anticancer immunotherapeutic vaccine platform technology, and Ad5/35, an adenovirus vector-based infectious disease preventive vaccine platform technology.

In November 2020, Cellid completed its Vaccine & Cell Gene Therapy GMP Center. It currently possesses production capabilities necessary for clinical-stage products and for products planned for commercialization after future GMP certification.

This content was produced with the assistance of AI translation services.